Background Image
Table of Contents Table of Contents
Previous Page  44 / 70 Next Page
Information
Show Menu
Previous Page 44 / 70 Next Page
Page Background

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 5, September/October 2019

286

AFRICA

Methods

The study evaluated 95 consecutive diabetic patients undergoing

primary PCI for STEMI. Patients were recruited to receive 25

μ

g/kg tirofiban bolus plus a maintenance dose of 0.15

μ

g/kg/

min infusion either IV (group A:

n

=

50) or IC (group B:

n

=

45)

for 24 hours.

We included adult patients between 18 and 75 years with a

clinical presentation of STEMI and specific ECG criteria in the

form of ST-segment elevation

1 mm in two or more contiguous

leads, except V2 and V3 had to be

1.5 mm in females,

ST-segment elevation

2.5 mm in males less than 40 years or

2 mm in males more than 40 years, or the presence of new-onset

or presumed new left bundle branch block.

13

The institutional ethics committee approved the study and all

patients signed informed consent.

Patients with marked uncontrolled hypertension (

180/110

mmHg), rescue PCI and emergency coronary artery bypass

grafting were excluded. Other exclusion criteria included patients

presenting with cardiogenic shock, severe liver or kidney failure,

bleeding diathesis, hypersensitivity or thrombocytopaenia with

tirofiban, platelets

<

150 000 cells/mm

3

, active internal bleeding,

history of ischaemic or haemorrhagic stroke within the last 30

days, atrioventricular malformation or aneurysm, neoplastic

aortic dissection, acute pericarditis, haemorrhagic retinopathy

and chronic haemodialysis.

Before the intervention all patients were treated with

acetylsalicylic acid (300 mg) and clopidogrel (600 mg). After

securing vascular access through the right femoral or radial

arteries, a total of 70–100 IU/kg unfractionated heparin IV bolus

was given, then an additional weight-adjusted unfractionated

heparin was given to achieve approximately 250 seconds of

activated clotting time (ACT).

In both groups, a bolus of 25

μ

g/kg of tirofiban was given

immediately after the guidewire crossed the lesion successfully

and antegrade flow was restored, aiming to secure maximum

concentration of the drug at the culprit lesion site and distal

microvascular bed. A bolus dose of tirofiban was given through

the guiding catheter in the infarct-related artery (IRA) at 30

seconds in the IC group. Maintenance IV tirofiban of 0.15

μ

g/kg/

min for 18 hours was started in both groups after the bolus dose.

An aspiration thrombectomy catheter was used if necessary

and, finally, a suitable drug-eluting stent (FDA approved) was

employed in the IRA in all patients.

Acetylsalicylic acid, a P2Y12 inhibitor (clopidogrel 75

mg), a high-intensity statin, beta-blocker and an angiotensin

converting enzyme inhibitor or angiotensin II receptor blocker

were prescribed as per the guidelines. When the activated

clotting time (ACT) was

<

160 seconds and/or four hours after

anticoagulation, the vascular sheath was removed by manual

compression.

The time to reperfusion was recorded from the onset of chest

pain until the visualisation of at least thrombolysis in myocardial

infarction (TIMI) 2 flow in the IRA during PCI. Before and after

coronary intervention, TIMI flow grades

14

and myocardial blush

grade (MBG)

15

were evaluated blindly by two interventional

cardiologists. For evaluation of left ventricular ejection fraction

(LVEF), the biplane modified Simpson’s method was used 48

hours after PCI and then again after 30 days.

The groups were compared for TIMI flow grades before and

after the intervention, and MBG, maximum C-reactive protein

(CRP) level, peak levels of both high-sensitivity troponin T

(hs-TnT) and CK-MB, time to peak for hs-TnT and CK-MB,

time to 50% ST resolution, and composite MACE rates at 30

days were recorded. Safety endpoints such as significant and

minor bleeding and thrombocytopenia were noted.

According to the dye density, the MBG score was classified

as grade 3

=

normal myocardial contrast density compared

to contrast density of a contra- or ipsilateral non-IRA, 2

=

moderate myocardial blush where contrast density is less

than that obtained from a contra- or ipsilateral non-IRA, 1

=

minimal myocardial blush or contrast density, and grade 0

=

no

myocardial blush.

16

MACE

17

included cardiovascular death, recurrent myocardial

infarction, stent thrombosis or target vessel revascularisation in

hospitalisation at one month. Thrombocytopenia was defined as

platelet count

<

100 000 cells/mm

3

.

16

Intracranial haemorrhage

and decrease in haemoglobin concentration

5 g/dl were

considered as major bleeding. Minor bleeding was defined as

10 to 15% decrease in haematocrit, blood loss with 3 to 5 g/dl

decrease in haemoglobin concentration, or

4 g/dl decrease in

haemoglobin concentration with no observed blood loss.

18

Statistical analysis

Patients’ data were collected, revised and analysed using the

statistical package for social sciences (SPSS) version 25.0 for

windows (IBM Corp, Armonk, NY, USA). Data are presented

as mean

±

standard deviation (SD), frequency and percentage.

Categorical variables were compared using the chi-squared (

χ

2

)

test. Continuous variables were compared with the Student’s

t

-test (two-tailed) and one-way ANOVA test for parametric

data with Bonferroni

post hoc

test to detect differences between

subgroups. The level of significance was accepted if the

p-

value

was

<

0.05.

Results

The two groups showed no statistically significant differences in

cardiovascular risk factors, baseline characteristics or medication

(Table 1). The mean age was 58.5

±

10.18 years in the IV group

and 55.90

±

11.66 years in the IC group. The groups showed no

significant differences in baseline level of glycated haemoglobin

(HbA

1c

) (

p

=

0.08), onset-to-balloon and door-to-balloon times

(

p

=

0.08, 0.3, respectively). Killip class frequency > 1 was 18%

in group A (IV) and 24% in group B (IC) (

p

=

0.33) (Table 1).

Peak CK-MB value was significantly lower in the IC group

than in the IV group (155.68

±

121, 192.4

±

86 U/l respectively)

(

p

=

0.021). Peak hs-TnT value was significantly lower in the

IC group than in the IV group (4291

±

334, 5342

±

286 ng/dl;

p

=

0.035). The percentage of patients with 50% resolution of

ST-segment was significantly higher in the IC group than in the

IV group (

p

=

0.016) (Fig. 1). The maximum CRP level, peak and

time to peak of both CK-MB and hs-TnT showed statistically

significant differences, as shown in Table 2. There was no

significant difference in LVEF between the groups 48 hours after

PCI (

p

=

0.632), but 30 days after PCI, the average LVEF in the

IC group was higher than in the IV group (

p

=

0.023).

Angiographic characteristics of the two groups are presented

in Table 3. Post-procedure TIMI 3 flow (Fig. 2) and MBG 3

were significant in the IC group (

p

=

0.045, 0.021, respectively).